MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.48
-1.98
-5.15%
After Hours: 36.18 -0.3 -0.82% 16:27 09/21 EDT
OPEN
37.85
PREV CLOSE
38.46
HIGH
37.85
LOW
36.01
VOLUME
454.17K
TURNOVER
--
52 WEEK HIGH
56.75
52 WEEK LOW
27.77
MARKET CAP
2.52B
P/E (TTM)
-6.8781
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the results of the final overall
GlobeNewswire · 12h ago
Agios' TIBSOVO improves OS, but not statistically significant vs. placebo in bile duct cancer
Agios Pharmaceuticals (AGIO) reports final overall survival ((OS)) analysis from its Phase 3 ClarIDHy trial of TIBSOVO in previously treated cholangiocarcinoma (bile duct cancer) with an isocitrate dehydrogenase 1 (IDH1) mutation.The data showed
Seekingalpha · 12h ago
Hedge Funds Have Never Been This Bullish On Agios Pharmaceuticals Inc (AGIO)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress
Insider Monkey · 5d ago
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Jonathan
GlobeNewswire · 09/08 21:01
2 Mid-Cap Healthcare Stocks to Buy Now
MotleyFool.com · 09/05 07:27
Agios Pharmaceuticals A Buy For Tibsovo, Mitapivat
Tibsovo sales, after weakness during launch, are ramping nicely.The therapy's label is likely to continue to be expanded for IDH1 mutant cancers.Mitapivat, if approved for PKD, could generate good revenue with orphan drug status.
Seekingalpha · 09/02 01:41
Who Has Been Buying Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 08/31 11:35
Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 08/29 16:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGIO stock price target is 65.45 with a high estimate of 80.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 300
Institutional Holdings: 72.52M
% Owned: 104.94%
Shares Outstanding: 69.11M
TypeInstitutionsShares
Increased
66
3.32M
New
74
703.64K
Decreased
59
5.50M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.77%
Pharmaceuticals & Medical Research
-2.28%
Key Executives
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Senior Vice President/General Manager
Orlando Oliveira
Chief Scientific Officer
Bruce Car
Other
Christopher Bowden
Senior Vice President
Darrin Miles
Director
David Scadden
Independent Director
Paul Clancy
Independent Director
Ian Clark
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
John Maraganore
Independent Director
Kaye Foster-Cheek
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average AGIO stock price target is 65.45 with a high estimate of 80.00 and a low estimate of 40.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AGIO
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.